The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 529.30% and ...

Here's why Eli Lilly is a no-brainer stock to buy on the dip ... Sales for breast cancer drug Verzenio jumped 32% year over ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...

Over the last 3 months, EPS estimates have seen 0 upward revisions and 13 downward. Revenue estimates have seen 16 upward ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

Eli Lilly’s relatively new products should continue to drive the sales growth. The company is expected to post over 2.5x y-o-y rise in Mounjaro sales to around $3.5 billion. Verzenio sales ...

Threats: Intense competition and patent expirations leading to generic competition.

Eli Lilly has a long history of developing drugs to treat a variety of conditions. For example, its third-best-selling drug Verzenio is used to help treat breast cancer, while its sixth-best ...

Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. The U.S. pharma giant reported third-quarter ...